(1888PressRelease)
June 13, 2009 - BAY 94-9172 binds to the beta amyloid protein in the brain, a pathological hallmark of Alzheimer’s disease. The data is being analyzed and results will be presented at this years International Conference on Alzheimer's Disease (ICAD) in Vienna.Additional information on BAY 94-9172 and related research & development programs will be presented at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 – 17, 2009.
“Beta amyloid has been proven to be a pathological hallmark of Alzheimer’s disease and it is accumulated in the brain very early in the course of the disease. Currently, the detection of this protein and, thus, the definitive diagnosis of Alzheimer’s disease is only possible upon post-mortem,” said Thomas Balzer, M.D., Head of Global Clinical Development Therapeutic Area Diagnostic Imaging. “Thus an in-vivo imaging method would be clinically very useful as it could help in the differentiation between different dementia forms and either exclude Alzheimer’s disease or make it very likely.
There is a high unmet medical need for a better and earlier differentiation between the various dementia forms and especially of Alzheimer’s disease. We hope that BAY 94-9172 can contribute to this for the patient’s benefit because an earlier and more accurate diagnosis allows for optimized care and treatment options,” he added.
Bayer Schering Pharma has extended its Phase II program to further expand the number of imaged individuals and will also begin its pivotal Phase III global clinical development program of BAY 94-9172 in the second half of this year.
Interesting contributions at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 – 17, 2009 are listed below: Test–retest variability of [18F]BAY94-9172 PET in Alzheimer’s disease and normal ageing
• Authors: Rowe, C.C.(1); Pejovska, S.1; Mulligan, R.S.(1); Chan, G.(1); Jones, G.(1); Fels, L.(2); Kusi, H.(2); Reininger, C.(2); Rhode, B.(2); Putz, B.(2); O'Keefe, G.(1); Masters, C.L.(3); Villemagne, V.L.(1)
(1)Austin Hospital, Melbourne, VIC, Australia; (2)Bayer Schering Pharma AG, Berlin, Germany; (3)The Mental Health Research Institute of Victoria, Melbourne, VIC, Australia.
• Scientific poster presentation at Neurology Posters, Poster Session I: Multimodality and Non-Radioactive Molecular Imaging, Educational Exhibits, Cardiovascular & Neuroscience Track Posters, Monday, June 15, 2:30 PM – 3:15 PM, Exhibit Hall E/F
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.
Find more information at www.bayerhealthcare.com.
###
